INVEX Therapeutics Ltd (IXC)
20mins delayed
Movement
1 Year Return
INVEX Therapeutics Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $55.71 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
IXC Statistics
28 September
1,085 / 2,238
ASX Size Rank
1yr Return
vs Sector (1yr)
+34.77%
vs ASX 200 (1yr)
+67.43%
$55.71 million
Market Cap
Share Issue
54.08 million
All Ords (%)
N/A
Short Sold
0.16%
Current Fundamentals
28 September
N/A
PE Ratio
EPS ($)
-0.06
Earnings Yield
-5.81%
NTA ($)
0.36
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Invex Therapeutics Ltd (IXC) is a biopharmaceutical company focused on the repurposing of an approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin.
Upcoming Calendar
| 19 Nov 2020 | AGM |
| 25 Feb 2021 | Report (Interim) |
| 27 Aug 2021 | Report (Prelim) |
| 27 Aug 2021 | Report (Annual) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Announcements provided by
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
IXC is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr David McAuliffe | Non-Executive Director | Mar 2019 |
|
| Ms Narelle Warren | Company Secretary, Non-Executive Director | Mar 2019 |
|
| Dr Jason Loveridge | Non-Executive Chairman, Non-Executive Director | Mar 2019 |
|
| Dr Alexandra J Sinclair | Chief Scientific Officer, Executive Director | Jun 2019 |
|
Director Transactions
IXC directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 22/11/19 | David McAuliffe | Issued | 200,000 | $0.710 | $142,000 | Issue of options. |
| 22/11/19 | Narelle Warren | Issued | 400,000 | $0.710 | $284,000 | Issue of options. |
| 22/11/19 | Jason Loveridge | Issued | 800,000 | $0.710 | $568,000 | Issue of options. |
| 22/11/19 | Alexandra Sinclair | Issued | 800,000 | $0.710 | $568,000 | Issue of options. |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 274 | 416 | 184 | 357 | 86 | 1,317 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Tattarang Pty Ltd | 13,841,670 | 23.45% |
| Tisia Nominees Pty Ltd | 5,000,000 | 8.47% |
| Jk Nominees Pty Ltd | 2,820,896 | 4.78% |
| Anthony Grist | 1,690,000 | 2.86% |
| Dr Jason Loveridge | 1,561,729 | 2.65% |
| Mr David Jerimiah Mcauliffe | 1,150,000 | 1.95% |
| HSBC Custody Nominees (Australia) Limited | 1,041,667 | 1.76% |
| Alexandra Jean Sinclair | 933,334 | 1.58% |
| Ms Kathryn Mary Salkilld | 650,000 | 1.10% |
| Citicorp Nominees Pty Ltd | 600,000 | 1.02% |
| The University Of Birmingham | 590,000 | 1.00% |
| Sunset Capital Management Pty Ltd | 500,000 | 0.85% |
| Bannaby Investments Pty Limited | 500,000 | 0.85% |
| Bnp Paribas Nominees Pty Ltd Hub 24 Custodial Serv Ltd Drp | 482,500 | 0.82% |
| Cityscape Asset Pty Ltd | 455,000 | 0.77% |
| Hsbc Custody Nominees (Australia) Limited-Gsi Eda | 430,000 | 0.73% |
| Sandhurst Trustees Ltd | 425,584 | 0.72% |
| Hsbc Custody Nominees (Australia) Limited-Gsi Eda I | 400,000 | 0.68% |
| J P Morgan Nominees (Australia Limited | 400,000 | 0.68% |
| Cs Third Nominees Pty Limited | 375,000 | 0.64% |
| All other shareholders | 42.64 % | |
The Top 20 Shareholders of IXC hold 57.36% of shares on issue.
IXC Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
IXC Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|---|---|
| 2020 | $1.30 | 30 June |
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Biopharmaceuticals.
Incorporated: --
Level 1, 38 Rowland St
Subiaco WA 6008
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.